Axsome secures top drug’s future with Teva patent settlement

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

Related posts

Moderna holds a ‘garage sale’; Roche defends obesity drug data

January 31, 2026

Sachet alcohol ban: Over 5m jobs, N800bn investments at risk – ACCI – EnviroNews

January 30, 2026

Source link